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Minimising bias in randomised controlled trials (RCTs) includes intention-to-treat (ITT) 
analyses. Hospice/palliative care RCTs are constrained by high attrition unpredictable when 
consenting, including withdrawals between randomisation and first exposure to the 
intervention. Such withdrawals may systematically bias findings away from the new 
intervention being evaluated if they are considered non-responders. This study aimed to 




A theoretical model was developed to assess the impact of withdrawals between 
randomisation and first exposure on i) study power and ii) effect sizes. Ten reported 




In the theoretical model, when 5% of withdrawals occurred between randomisation and first 
exposure to the intervention, change in power was demonstrated in binary outcomes (2.0-
2.2%), continuous outcomes (0.8-2.0%) and time-to-event outcomes (1.6-2.0%), and odds 
ratios were changed by 0.06-0.17. Greater power loss was observed with larger effect sizes.  
 
Withdrawal rates were 0.9%-10% in the ten reported RCTs, corresponding to power losses of 
0.1%-2.2%. For studies with binary outcomes, withdrawal rates were 0.3-1.2%, changing 




If blinding is maintained and all interventions are available simultaneously, our model 
suggests that excluding data from withdrawals between randomisation and first exposure to 
the intervention minimises one bias. This is the safety population as defined by the 
International Committee on Harmonisation.  
 
When planning for future trials, minimising the time between randomisation and first 
exposure to the intervention will minimise the problem. Power should be calculated on 
people who receive the intervention. 
 
Key words: Intention-to-treat analyses, palliative care, randomised controlled trials, good 
clinical practice, study withdrawal, imputation, missing data, International Committee on 
Harmonization 
 




The International Committee on Harmonization Statistical Principles for Clinical Trials (ICH 
E9) guideline has been adopted internationally as the authoritative document on the conduct 
and analysis of clinical trials.1 Included in the ICH E9 guideline is a section on the study 
populations to be included in the analyses, and the reasons for choosing one population over 
another, depending on circumstances.1 For example, it outlines the times at which one should 
use an intention-to-treat (ITT) analysis and contrasts that with when it may be appropriate to 
use a per protocol analysis.1 
 
ITT analyses aim to evaluate the primary outcome in randomised controlled trials (RCTs) to 
minimise bias and ensure that the point estimate is as close to the “truth” as possible.1 2 With 
an ITT approach in mind, the sample size is calculated using the parameters related to the 
primary endpoint, attempting to only include the number of participants required to answer 
the question in the most robust way. This also ensures an ethical approach as studies should 
be no bigger than required to answer the question (as estimated from pre-specified power) so 
that participants are not unnecessarily enrolled and exposed to harms or not offered benefits 
that may have already been defined by the study. 
 
Two time points are crucial when considering the design, conduct and analysis of RCTs 
within an ITT context: randomisation and first exposure to the intervention. The ICH E9 
guideline recognises that sub-groups of people might withdraw from RCTs at different stages 
of study engagement, including eligible people who were randomised:1 
 
(1) but 
a) were not exposed to the intervention; and 
b) provided no further post-randomisation data; while 
c) participants, clinicians and other research staff were still blinded to their allocated arm; 
 
(2) and were not exposed to the intervention, but provided no further data; 
 
(3) and were exposed to the intervention, and provided further data, but withdrew prior to the 
primary endpoint. 
 
This current study deals entirely with this first group where people withdrew between 
randomisation and first exposure to the intervention. 
 
For most RCTs, participants who withdraw between randomisation and first exposure to the 
intervention constitute an extremely small proportion of participants and their withdrawal 
consequently makes little difference to the power of the studies or its conclusions. By 
contrast, this proportion is appreciable in hospice / palliative care studies.  
 
In hospice/palliative care RCTs, there are three issues that suggest a strict application of the 
ICP E9 guidance be applied in order to ensure that this source of bias away from the new 
intervention is minimised: 
 
- Hospice/palliative care studies tend to seek a clinically significant difference between 
groups requiring a large delta between groups.3-6 Because of this, sample sizes tend to 
be smaller, potentially leading to a greater loss of power when people withdraw.2 
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- Withdrawal of study participants cannot be predicted at enrolment or it would be 
unethical to enrol those persons in the first instance. A proportion of these people will 
withdraw between randomisation and first exposure to the intervention. 
 
- The proportion of subsequent withdrawals after intervention commencement at any 
point prior to the primary endpoint is also higher,7 even when the trial measures the 
endpoint at the earliest clinically appropriate time for the intervention under study. In 
some hospice/palliative care RCTs, total withdrawals any time between randomisation 
and the endpoint can be as high as 50%,8 and sufficient to introduce bias.7 Importantly, 
most withdrawals will be unrelated to the intervention(s) being tested.2 7 9 
 
An unnecessary bias may be avoided if withdrawals between randomisation and first 
exposure to the intervention are excluded from the analysis. Currently, they are assumed to be 
non-responders (a conventional view of ITT as they are post-randomisation), potentially 
introducing a systematic bias away from the intervention being evaluated. However, ICH E9 
directly addresses such a situation, offering an alternative. It states that: ‘The intention-to-
treat principle would be preserved despite the exclusion of [people who withdraw between 
randomisation and first exposure to the intervention] provided, for example, that the decision 
of whether or not to begin treatment could not be influenced by knowledge of the assigned 
treatment.’1[p.1929] Crucially, there is no indication that the interpretation and applicability of 
the ITT principle changes with such exclusions from the data sets. The ICH E9 considers 
such analyses to be unambiguously ITT; therefore, analyses that exclude the data of 
participants between randomisation and first exposure to the intervention should not be seen 
as ‘modified’ ITT.  
 
The unanswered question is whether applying the conventional interpretation of ITT to the 
primary analysis (which assumes withdrawals before exposure to the intervention are non-
responders) may introduce bias against the finding of effectiveness and therefore justify 
exclusion of these patients from the analysis. Conversely, if data from such participants are 
excluded, there will be a modest but at times appreciable loss of power and potential to 
underestimate the adverse event rates. 
 
Given concerns about potentially higher rates of attrition between randomisation and first 
exposure to the intervention, which contributes to attrition that occurs in hospice/palliative 
care RCTs, this paper sought to explore this problem through three approaches: 
 
1. Demonstrate theoretically how inclusion of the data from consented participants who 
withdraw between randomisation and first exposure to intervention (with the 
assumption that they are non-responders in primary analyses) reduces the power and 
effect size of a study using three different types of primary outcome measures (binary, 
continuous and time-to-event data); 
2. Quantify these rates in a convenience sample of ten completed double-blind, placebo-
controlled phase III hospice/palliative care studies while evaluating the impact on the 
power and effect size on these selected ten phase III studies; and 
3. Offer recommendations for future conduct and analyses of all hospice/palliative care 
phase III studies. 
 
If power is affected appreciably, a strong case could be made for a change to the approach to 
analyses without compromising the interpretation and applicability of the ITT principle as 





Phase 1. Theoretical model  
Illustrative hypothetical models were developed reflecting hypothetical studies with three 
different effect sizes (small, medium and large) and three types of outcome measures (binary, 
continuous and time-to-event). For the purpose of these theoretical models, the authors 
assumed that: 1) the hypothetical studies had already closed for recruitment, and 2) all 
withdrawals were only between randomisation and first exposure to the intervention. The 
sample size calculation package nQuery (version 8.0) was used to generate these three 
theoretical models corresponding to the type of primary outcome measure: 
 
1. Binary outcome data. The authors assumed the proportion of responders in the theoretical 
control group was 30% while in the intervention group responders accounted for 40% 
(small effect size (10%)), 50% (moderate effect size (20%)) and 60% (large effect size 
(30%)) of participants. This corresponded to odds ratios of 1.56, 2.33 and 3.50, for small, 
medium and large size, respectively. 
2. Continuous data. The standard deviation was set at 1.0, and mean differences between 
groups of 0.2, 0.5 and 0.8 (to reflect small, medium and large effect size, respectively) 
were used.10 
3. Time-to-event data. Assuming hazard ratios of 0.8, 0.6, and 0.4 (for small, medium and 
large effect size, respectively), event rates by the primary endpoint were 50% and 42% (in 
the control group), and 31.5% and 17.7% (in the intervention group). 
 
Impact on power 
For each type of outcome measure, we first generated the sample size with appropriately 
fixed 0.05 significance level and 80% power reflecting levels most frequently used in 
hospice/palliative care trials to ensure the models reflected current practice. We then 
calculated a revised sample size and power calculation based on the assumption that 5% of 
study participants withdrew between randomisation and first exposure to the intervention, and 
were excluded from the analysis. 
 
Impact on odds ratio 
Studies with binary primary outcomes were employed to assess the theoretical impact of 5% 
withdrawals between randomisation and first exposure to the intervention on the studies odds 
ratios. Assuming 0.05 significance level, 80% power and three study effect sizes (small, 
medium and large), we first calculated the odds ratios of the studies assuming these 
withdrawals were included in the analysis as non-responders. We then repeated the 
calculations assuming these withdrawals were excluded from the analysis. 
 
For continuous or time-to-event analyses, withdrawal between randomisation and first 
exposure to the intervention do not allow imputation given the lack of data. If the study 
includes such people in the overall a priori recruitment total, the study will again be at risk of 
being underpowered. 
 
Phase 2. Assessing the model using phase III hospice/palliative care studies 
 
A convenience sample of ten RCTs published in the hospice/palliative care literature between 
2003 and 2018 were used to evaluate the problem. The selected trials were led by four 
clinical research teams from around the world, and were double-blind, placebo-controlled 
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randomised trials testing pharmacological interventions for symptom control in people with 
advanced life-limiting illnesses. Crossover and parallel-arm studies were included. 
 
Study characteristics retrieved from study protocols and published articles included: study 
design (randomisation, blinding, and treatment/control intervention), the primary outcome, 
number of sites involved, days between successful screening and first exposure to the study 
intervention, sample size, number of participants randomised, and number of participants 
withdrawn before first intervention. 
 
Study characteristics were summarised using counts, percentages, medians, interquartile 
ranges, standard deviation, and means as appropriate. Descriptive statistics were used to 
present the types of withdrawal. 
 
For each study, we calculated the proportion of participants who withdrew between 
randomisation and first exposure to the intervention. We then calculated changes in the power 
that would have occurred if these people’s data were excluded from the analysis. For studies 
with binary primary outcomes, the impact on changes in odds ratio was also examined for 




The use of secondary, de-identified data did not require additional ethics approval. Approvals 
for primary data collection were obtained from all relevant Human Ethics Research 




1. Results of the theoretical modelling 
 
Impact on power 
For hypothetical studies with binary outcomes, a 5% rate of withdrawal between 
randomisation and first exposure to the intervention lead to 2.0-2.2% difference in power 
depending on the inclusion or exclusion of these data from the analysis (Table 1). For studies 
with continuous outcomes, a 5% attrition caused 0.8-2.0% power loss, depending on the 
study effect sizes; greater power loss was observed in studies with smaller effect sizes. For 
studies with time-to-event outcomes, the power loss associated with 5% attrition ranged from 
1.6% to 2.0%; again, greater loss of power was observed in studies with smaller effect sizes. 
 
Impact on odds ratio 
For hypothetical studies with binary outcomes, the impact of counting withdrawals as non-
responders on odds ratios ranged from 0.06 to 0.17 (Table 2). Excluding the withdrawals 
changed the odds ratios; greater loss of power was seen with larger effect sizes. 
 
2. Assessing the model using phase III hospice/palliative care studies 
 
Study characteristics 
Ten studies were conducted across 85 sites in Australia, Norway, and the UK (Table 3). The 
total number of participants randomised to the studies was 1710. The median time to primary 
endpoint was 7 days (IQR 4-16). In seven studies,11-17 median time from screening to first 
exposure to the study intervention was 1 day, while for three studies,18-20 these data were not 
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available). In three studies,12 14 17 there was a run-in period prior to receiving the first study 
intervention for a median of 1 day. The a priori power calculations for seven studies were set 
at 80%,11-15 17 19 one study was powered to 85%16 and two were powered to 90%.18 20 
 
The total number of participants who were randomised but were not exposed to the 
intervention was 40, which was 2.34% of the 1710 patients randomized in all ten studies. 
 
Table 3 presents the impact of withdrawals between randomisation and first exposure to the 
intervention on power loss and odds ratio changes for all phase III studies. Primary outcomes 
were binary (four studies);12-14 16 continuous (five studies);11 18-20 or time-to-event (one 
study).15 
 
Only one study had no withdrawals between randomisation and first exposure to the 
intervention.12 For all other studies, this proportion ranged from 0.9% to 10.0%, which 
corresponded to 0.1-2.2% power loss reflecting increasing loss of power with and increasing 
proportion of such withdrawals.13-20 The exception to this was Agar et al.11 where a 4.4% rate 
corresponded to a 0.1% loss of power; with the power loss being mitigated because of the 
baseline and follow-up outcome correlation was considered in the sample size calculation. 
 
For studies with binary outcomes,12-14 16 withdrawal between randomisation and first 
exposure to the intervention ranged from 0.9% to 2.6%, with corresponding 0.01-0.22 




Our theoretical model demonstrated that an ITT population that excluded participants who 
withdrew between randomisation and first exposure to the intervention resulted in a loss of 
power of approximately 2% compared to an analysis that included these participants, 
irrespective of the primary outcome measures employed. Effect size did not impact on this 
loss of power in studies with binary outcomes although, as expected from first principles, 
power loss was relatively less in trials with continuous or time-to-event outcomes with 
moderate or large effect sizes. In studies with binary outcomes, excluding withdrawals 
changed the odds ratio; the loss of power was greater with larger effect sizes. In studies with 
large effect sizes, the odds ratio changed by approximately 17%. 
 
Across ten trials conducted in people with advanced life-limiting illnesses, 2.34% of 
consented participants withdrew between randomisation and first exposure to the 
intervention. One study experienced no withdrawals and one study had a withdrawal rate of 
10%. The loss of power paralleled the rate of withdrawal and was similar to the theoretical 
model, ranging between 0.1%-2.2%. The expected power loss was not seen in Agar et al.11 in 
which a 4.4% rate of withdrawals led to only 0.1% loss of power because the method of 
sample size calculation mitigated the impact of withdrawals. By contrast, in the studies that 
used a binary outcome, excluding withdrawals between randomisation and first exposure to 
the intervention changed the odds ratio by as much as 22%. 
 
Although attrition between randomisation and first exposure to the intervention represents a 
relatively small proportion of participants in studies in general, the phenomenon is relevant to 
RCTs in people with advanced life-limiting illnesses given that overall sample sizes in 
symptom control studies are often relatively small because of the large delta required for 
clinically relevant differences of effect size between groups. This impact is further amplified 
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because most hospice/palliative care RCTs are powered to 80% (including seven of the ten 
studies in our convenience sample). The smaller the trial, the greater the loss of power with 
withdrawals as each individual carries more “power”. 
 
Withdrawals between randomisation and first exposure to the intervention from binary 
outcome trials affect the odds ratio if included in the analysis as non-responders, especially in 
the typically large effect size trials in palliative care. A 22% change in odds ratio represents a 
clinically relevant difference potentially. Participants who withdraw between randomisation 
and first exposure to the intervention from trials using continuous or time-to-event outcome 
as their primary powered endpoint will not contribute to the analysis unless missing data are 
imputed. Yet, they provide no data for imputation as they have not been exposed to the 
intervention. Including the population who have no exposure to the intervention (or control) 
and treating their data in the same way as any participants who has been exposed to the 
intervention does not help to minimise a potential bias. 
 
Implications for trial conduct and analysis 
 
Excluding people who withdraw between randomisation and first exposure to the intervention 
effectively means that the population described for the primary analysis in hospice/palliative 
care RCTs (subject to certain caveats) would be both the ITT population but also the safety 
population – i.e. those who have had exposure to the intervention and can exhibit treatment 
emergent adverse events. The theoretical model and its application to our convenience 
sample of ten studies suggest that this use of the ‘safety population’ (defined as ‘[…] 
those…who received at least one dose of the investigational drug’1[p.1934]) may pose 
advantages for RCTs in hospice/palliative care and other frail populations. 
 
However, in order for this argument to be valid, there are four criteria that must be met. In 
order to exclude study participants who withdraw between randomisation and first exposure 
to the intervention from an ITT analysis data set, criteria include: 
 
1. As noted in the ICH E9 guideline, the study must still be blinded at the time of 
withdrawal.1 This is to ensure that any decisions about the start of the intervention are 
not influenced by knowledge of the assigned intervention.1 This may preclude some 
cluster-randomised studies that are single-blinded or unblinded. 
2. Access to each arm must happen simultaneously.2 There can be no delay to the access 
to one arm, or unblinding will have occurred. (This was a principle that led to the ITT 
principle being articulated in the first place.) 
3. As a check on reverting to the original ITT principles, the drop-out rate per arm 
should be of the same order of magnitude.2 This is to ensure that the withdrawal is due 
to natural disease progression or sudden death, rather than the study intervention.2 
4. The impact of excluding the data from such participants should be evaluated as a 
sensitivity analysis.2 
 
Recognising that attrition between randomisation and first exposure to the intervention is a 
potential problem in hospice/palliative care RCTs suggests that the design of such studies 
should be reconsidered. The following is a proposed hierarchy of changes that may help 
investigators to reduce this risk. 
 
1. Closed studies 
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If the conditions for excluding participants between randomisation and first exposure to the 
intervention are met, it is reasonable to consider excluding these data from the primary 
analysis. The requirements for ITT will be maintained (and therefore the resultant analysis 
should not be labelled a modified ITT), and the effect of the new intervention will not be 
under-estimated. This will, however, lead to a loss of power. 
 
2. Studies currently open to recruitment 
Additional recruitment to reach the original sample size may be possible if participants 
withdraw between randomisation and first exposure to the intervention (and this is stipulated 
in the protocol). The withdrawals should not be counted towards the proposed optimal study 
recruitment. 
 
3. Designing future studies 
Ideally, participants should not be randomised until they are ready to be exposed to the 
intervention, although this is not always practical. If there is a run-in period, randomisation 
should occur at the end of that period. Alternative sample size calculation can also be used, 
such as the one in Agar et al.,11 which seems to mitigate against loss of power due to 
withdrawals between randomisation and first exposure to the intervention. 
 
Implications for future research 
 
Prediction of eligible participants most likely to withdraw prior to any exposure to the 
intervention would enable refinement of eligibility criteria. End-of-study attrition rates in 
supportive/palliative oncology studies have been shown to be associated with higher baseline 
symptom burden (among other factors).21 Determining any relationship between participants’ 
overall performance status, disease status and co-morbidities at baseline and their withdrawal 
before they can be exposed to the intervention, may help to refine recruitment strategies in 




A priori estimates of withdrawal proportion were not available nor were detailed breakdowns 
of withdrawal between first exposure to the intervention and the primary endpoint for the ten 
included phase III studies. Understanding in more detail study withdrawal rates in phase III 
hospice/palliative care studies between randomisation and each study’s primary endpoint will 




Excluding withdrawals between randomisation and first exposure to the intervention from the 
primary analysis in hospice/palliative care RCTs still fully honours the principles of ITT, 
formed from the population that is best described as the safety population – those people who 
have been exposed to the intervention at least once. Although the loss of power may be 
modest, the impact of withdrawals between randomisation and first exposure to the 
intervention can be minimised or even eliminated by attention to trial design for new studies, 
and managing loss of power by additional recruitment for studies currently open. Exclusion 
of data from these participants would minimise one small but appreciable bias in reporting 
clinical trial outcomes. 
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Table 1. The impact of withdrawals between randomisation and first exposure to the intervention in ITT analyses 
on losing study power 
 Binary outcomes (e.g. response rate, etc.) 













Proportion in control 
group 
30% 30% 30% 30% 30% 30% 
Proportion in 
intervention group 
40% 40% 50% 50% 60% 60% 
Effect size 10% 10% 20% 20% 30% 30% 
Odds ratio 1.556 1.556 2.333 2.333 3.500 3.500 
N per group 356 338 93 88 42 40 
Power  80% 77.9% 80% 77.8% 80% 78.0% 
Power loss 2.1%  2.2%  2.0%  
 Continuous outcomes (e.g. quality of life, etc.) 













Mean difference 0.2 0.2 0.5 0.5 0.8 0.8 
SD 1.0 1.0 1.0 1.0 1.0 1.0 
Effect size 0.2 0.2 0.5 0.5 0.8 0.8 
N per group 394 374 64 61 26 25 
Power  80% 78.0% 80% 78.2% 80% 79.2% 
14 
Power loss 2.0%  1.8%  0.8%  
 Time-to-event outcomes (e.g. overall survival, etc.) 













Event rate at 
primary endpoint in 
control group 
50% 50% 50% 50% 50% 50% 
Event rate at 
primary endpoint in 
intervention group 
42% 42% 31.5% 31.5% 17.7% 17.7% 
Hazard ratio 0.8 0.8 0.6 0.6 0.4 0.4 
N per group 589 560 106 101 33 31 
Power  80% 78.0% 80% 78.1% 80% 78.4% 
Power loss 2.0%  1.9%  1.6%  
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Table 2. The impact of counting withdrawals between randomisation and first exposure to the intervention as 
non-responders on changing odds ratio 
 Binary outcomes (e.g. response rate, etc.) 















30% 25% 30% 25% 30% 25% 
Responders in 
intervention group 
40% 35% 50% 45% 60% 55% 
Odds ratio 1.556 1.615 2.333 2.455 3.500 3.667 
Odds ratio 
difference 
0.059 0.122  0.167  
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Table 3. The impact of withdrawals between randomisation and first exposure to the intervention on potential power loss 
and odds ratio changes for 10 randomised controlled trials in hospice/palliative care 





















 Binary outcomes 
Currow et al.13 Treatment 
response 





ne (n=67) or 












1 4/185 (2.2%) 0.5% 0.06 
Fallon et al.14 Treatment 
response 









Currow et al.12 Treatment 
response 





2 0/223 (0%) 0% 0 
 Continuous outcomes 
Klepstad et al.18 Time needed 
to achieve pain 
relief 











Oxberry et al.19 NRS 
breathless 
severity score 






Not available 2/39 (5.1%) 1.8% Not applicable 
 





Not available 1/50 (2%) 1.0% Not applicable 
Currow et al.17 Breathlessness 
change 
287 in total; 
morphine 
(n=146) or 











0 11/249 (4.4%) 0.1% Not applicable 
 Time-to-event outcomes 
Fallon et al.15 Duration of 
analgesic 
benefit 





1 3/214 (1.4%) 0.6% Not applicable 
aThe power loss calculation corresponds to Table 1; bThe odds ratio change is applicable to studies with binary primary outcome (response rate, etc.) and corresponds to 
Table 2; cCIBP – Cancer-Induced Bone Pain; HF – Heart Failure; NRS – Numerical Rating Scale; NuDESC – Nursing Delirium Screening Scale. 
